Symbiotic Capital Brings Together a
World-Class Team of Scientists, Financiers and Entrepreneurs to
Provide Credit Partnerships to Compelling Life Science Companies
Around the World
Symbiotic Capital Held Final Closing of its
Inaugural Fund and Has Already Originated Hundreds of Millions of
Dollars of Credit Facilities
LOS
ANGELES, Aug. 6, 2024 /PRNewswire/ -- Symbiotic
Capital ("Symbiotic"), a global life science credit firm, was
officially unveiled today with more than $600 million in capital committed and targeted
for investments and co-investments. Symbiotic Capital is affiliated
with Bellco Capital ("Bellco"), the Los Angeles-based investment firm founded by
biotechnology entrepreneur Dr. Arie Belldegrun. Symbiotic will
structure and originate credit solutions to compelling life science
companies to support scientific innovation across biotechnology,
medical devices, diagnostics, tools, synthetic biology, and other
healthcare subsectors.
"The life science industry continues to experience unprecedented
productivity, innovation and scientific discovery as biotechnology
and technology converge," said Symbiotic Co-Chairman Dr.
Arie Belldegrun. "As the cost to
research, develop and commercialize innovative therapeutics,
devices, tools and other products has increased substantially
throughout the sector, credit has become an increasingly important
financing tool for established healthcare enterprises. With
Symbiotic Capital, we have designed a science-first credit platform
to fuel those endeavors."
"Over the past three decades, Bellco's ecosystem has partnered
with visionaries across life sciences to build and invest in
compelling enterprises and develop labs and innovation campuses. We
are incredibly excited to launch Symbiotic Capital and unlock our
ecosystem's resources, relationships, insights and 'patients first'
mentality for borrowers throughout the healthcare industry," said
Josh Bradley, Chief Investment
Officer of Bellco and Symbiotic Co-Founder.
Symbiotic's integrated science team includes Dr. Franz Humer (former Chairman and CEO of Roche),
Dr. Toby Cosgrove (former President
and CEO of the Cleveland Clinic), UCLA
scholars Dr. Jim Economou and Dr.
Owen Witte, leading life science
venture investors Amy Schulman and
Helen Kim, and veteran life science
company builder Joshua Kazam.
"Traditional financing institutions have struggled to meet the
increasing capital needs for growing healthcare companies due to
the complexity of the underlying science and competitive
environment," said Russell
Goldsmith, Symbiotic Co-Chairman and the former Chairman and
CEO of City National Bank. "With Symbiotic Capital, we've assembled
a uniquely qualified, multi-disciplinary and experienced team that
brings together the best of traditional credit underwriting with
deep sector fundamentals and expertise."
As life science companies fund ongoing research and development,
capital expenditures and commercialization activities, credit
financings can minimize the equity demands otherwise necessary for
such operations and expansion.
"Credit is a more powerful tool when provided by a trusted
partner that is aligned and able to support the borrower's entire
enterprise," said Himani Bhalla,
Symbiotic Chief Investment Officer and Co-Founder. "Symbiotic's
offerings build upon the traditional benefits of credit and provide
partner-driven relationships to innovative life science companies
around the world."
About Symbiotic Capital (symbcap.com)
Symbiotic Capital is a life science credit firm that brings
together decades of experience across life sciences, finance, and
entrepreneurship. Our integration into a global life science
ecosystem empowers us to provide lending solutions to fuel the
growth of established life science companies around the world.
Life Science Credit. For Science, By Science.
For more information, please visit www.symbcap.com.
About Bellco
Capital (bellcocapital.com)
Bellco Capital is an investment firm founded in 2003 by Drs.
Rebecka Belldegrun, M.D. and Arie Belldegrun, M.D. Over the
decades, the Bellco ecosystem has incubated and built leading life
science companies, invested in transformational science and
developed life science real estate across the globe, generating
immense value creation in the process.
For more information, please
visit www.bellcocapital.com.
Contacts
Dan Boyle
dan@boylepr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/symbiotic-capital-a-first-of-its-kind-life-science-credit-firm-launches-with-more-than-600-million-raised-302214790.html
SOURCE Symbiotic Capital